share_log

4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Dogan Meeshanthini

4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Dogan Meeshanthini

4/A:持股變動聲明(修正)-高管 Dogan Meeshanthini
美股SEC公告 ·  2024/10/07 23:33

Moomoo AI 已提取核心訊息

Cardio Diagnostics Holdings, Inc. CEO Dogan Meeshanthini completed a purchase of company stock on September 6, 2024. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Meeshanthini's direct holdings in the company increased to a total of 1,655,429 shares. The transaction, characterized as an open market or private purchase, reflects the CEO's direct investment in the company's stock.
Cardio Diagnostics Holdings, Inc. CEO Dogan Meeshanthini completed a purchase of company stock on September 6, 2024. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Meeshanthini's direct holdings in the company increased to a total of 1,655,429 shares. The transaction, characterized as an open market or private purchase, reflects the CEO's direct investment in the company's stock.
卡迪歐診斷控股公司首席執行官多甘·梅珊蒂尼於2024年9月6日完成了一筆公司股票交易。該交易涉及以每股0.29美元的價格收購了68,965股普通股。在此交易後,梅珊蒂尼在公司的直接持股增加到總共1,655,429股。這筆交易被稱爲是公開市場或私人收購,反映了首席執行官對公司股票的直接投資。
卡迪歐診斷控股公司首席執行官多甘·梅珊蒂尼於2024年9月6日完成了一筆公司股票交易。該交易涉及以每股0.29美元的價格收購了68,965股普通股。在此交易後,梅珊蒂尼在公司的直接持股增加到總共1,655,429股。這筆交易被稱爲是公開市場或私人收購,反映了首席執行官對公司股票的直接投資。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息